MYD88-silencing hUCMSC-derived extracellular vesicles alleviate sepsis- associated encephalopathy by modulating neurovascular and microglial inflammation

When the body fights a severe infection, the immune system launches a massive defense to clear the threat. Sometimes, however, this defense does not shut down when the infection is gone. Instead, it lingers, turning against the brain and causing a condition known as sepsis-associated encephalopathy. This is not a direct infection of the brain, but a diffuse dysfunction where the brain becomes inflamed, leading to confusion, memory loss, and long-term cognitive decline. The problem is that current medical treatments focus on stopping the initial infection and supporting the patient's organs, but they offer no way to stop the brain from continuing to suffer once the patient survives. For many survivors, the fog of brain fog and the loss of mental sharpness can last for years, with no established strategy to repair the damage.

A team of researchers has now identified a specific molecular switch that keeps this brain inflammation running long after the infection has cleared, and they have developed a way to turn that switch off. The study focuses on a protein called MYD88, which acts as a central messenger for the immune system. In healthy brains, this protein helps coordinate a quick response to danger. But in mice that survived a severe infection, the researchers found that MYD88 remained stuck in the "on" position within the brain's immune cells and the cells lining the blood vessels. This persistent signal drove a cycle of inflammation and oxidative stress that damaged the delicate connections between neurons and broke down the barrier that protects the brain from the bloodstream. To fix this, the scientists engineered tiny, natural bubbles called extracellular vesicles, harvested from human umbilical cord stem cells. They loaded these bubbles with a molecular tool designed to silence the MYD88 gene. When injected into the bloodstream of infected mice, these engineered bubbles traveled to the brain, entered the immune cells, and successfully switched off the overactive MYD88 signal. The result was a restoration of the blood-brain barrier, a reduction in brain inflammation, and a remarkable recovery of memory and behavior, suggesting a new path to treat the lingering effects of sepsis.

The journey to this discovery began by mapping the timeline of the brain's recovery after a severe infection. The researchers used a standard model of sepsis in mice, where a small puncture in the intestine triggers a systemic infection. They waited for the mice to survive the acute phase and then checked their brains at various intervals: one month, three months, and six months later. They found that while most signs of the infection faded, the levels of the MYD88 protein remained dangerously high in the brain's immune cells and blood vessel cells for at least a month. This elevation was not a fleeting spike but a sustained state that coincided with the period when the mice began to show signs of cognitive trouble. By looking closely at the brain tissue, the team saw that this overactive protein was present in the cells that form the brain's blood vessels and in the microglia, the brain's resident immune cells. This suggested that the problem was not just in one part of the brain, but in the very infrastructure that keeps the brain safe and functioning.

To tackle this persistent signal, the researchers turned to a delivery system that the body already uses to communicate between cells. They collected extracellular vesicles, which are tiny, membrane-bound packages naturally released by human umbilical cord stem cells. These vesicles are small enough to travel through the bloodstream and can carry cargo like proteins and genetic material from one cell to another. The team engineered these vesicles to carry a specific set of instructions designed to silence the MYD88 gene. They used a process called electroporation, which uses a brief electrical pulse to push the genetic instructions into the vesicles without damaging them. Before testing this in living animals, they confirmed that the vesicles could protect their cargo from being destroyed by enzymes in the blood and that they could successfully enter brain cells to turn down the MYD88 signal. They also verified that these engineered vesicles could cross the blood-brain barrier, a tightly controlled wall that usually keeps large molecules out of the brain, and that they were taken up by the microglia once inside.

With the delivery system ready, the researchers moved to the treatment phase. They waited until three days after the mice had survived the infection, a point when the acute crisis had passed but the brain damage was already underway. They then injected the engineered vesicles into the mice's tail veins once a day for six days. This timing was crucial because it tested whether the treatment could reverse damage that had already started, rather than just preventing it. The results were striking. The mice that received the MYD88-silencing vesicles showed a significant reduction in the leakage of their blood-brain barrier, a sign that the protective wall had been repaired. In contrast, mice that received unmodified vesicles or no treatment continued to show signs of a leaky barrier. The treatment also lowered the levels of MYD88 in the brain's blood vessels and immune cells, effectively turning down the inflammatory signal that had been driving the damage.

The benefits of this treatment extended deep into the structure of the brain. When the researchers examined the hippocampus, the region responsible for memory, under a powerful microscope, they saw that the untreated mice had mitochondria—the energy powerhouses of the cell—that were swollen and damaged. The connections between neurons, known as synapses, were also thin and disorganized. In the mice treated with the engineered vesicles, these structures looked much healthier. The mitochondria regained their normal shape, and the synaptic connections were thicker and more robust, resembling those of healthy, uninfected mice. This structural recovery was matched by a shift in the brain's chemical environment. The treatment reduced the production of harmful inflammatory molecules and restored the levels of natural antioxidants that protect cells from stress. It also encouraged the brain's immune cells to switch from a state of constant attack to a state of repair, marked by an increase in a protein called TREM2, which helps cells clean up debris and heal tissue.

Finally, the researchers asked whether these biological changes translated into real-world improvements in how the mice thought and behaved. They put the mice through a series of tests designed to measure anxiety, spatial memory, and the ability to recognize new objects. The untreated mice, despite having survived the infection, acted as if they were anxious, avoiding the center of open spaces, and they struggled to remember where they had been or to recognize new items. The mice treated with the engineered vesicles, however, behaved much like healthy mice. They explored their environment with confidence, remembered the location of a hidden escape box in a maze, and showed a clear preference for new objects over familiar ones. The treatment did not just reduce inflammation; it restored the mice's ability to learn and remember, reversing the cognitive deficits that typically follow a severe infection.

This study suggests that the key to treating the long-term brain damage caused by sepsis may lie in silencing a specific molecular signal that keeps the immune system stuck in overdrive. By using engineered vesicles to deliver a targeted genetic tool, the researchers were able to stop the inflammation, repair the blood-brain barrier, and restore the brain's structure and function. While this work was done in mice, it points to a potential new strategy for human medicine: a cell-free therapy that can be administered after the initial infection is under control to prevent the brain from suffering long-term consequences. The approach offers a way to target a specific intracellular protein that has been difficult to reach with traditional drugs, opening a door to treatments that could help survivors of sepsis regain their mental sharpness and quality of life.